SEC Comment Letter 0000000000-24-006540 to Elicio Therapeutics, Inc. (ELTX) (CIK 0001601485) (ELTX)
Elicio Therapeutics, Inc. (ELTX) (CIK 0001601485)
Date: June 6, 2024 · CIK: 0001601485 · Accession: 0000000000-24-006540
AI Filing Summary & Sentiment
File numbers found in text: 333-279925
Letter
United States securities and exchange commission logo June 6, 2024 Robert Connelly President & Chief Executive Officer Elicio Therapeutics, Inc. 451 D Street 5th Floor Boston, MA 02210 Re:Elicio Therapeutics, Inc. Registration Statement on Form S-3 Filed June 3, 2024 File No. 333-279925 Dear Robert Connelly: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel A. Bagliebter, Esq.
Show Raw Text
United States securities and exchange commission logo
June 6, 2024
Robert Connelly
President & Chief Executive Officer
Elicio Therapeutics, Inc.
451 D Street
5th Floor
Boston, MA 02210
Re:Elicio Therapeutics, Inc.
Registration Statement on Form S-3
Filed June 3, 2024
File No. 333-279925
Dear Robert Connelly:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel A. Bagliebter, Esq.